title: Effective emetic control during conditioning of children for bone marrow transplantation using ondansetron, a 5-HT3 antagonist.
abstract: Preparation for bone marrow transplantation (BMT) uses the extremely emetogenic combination of chemotherapy and total body irradiation (TBI). Ondansetron is a selective 5-HT3 antagonist and has clear anti-emetic capabilities. The efficacy of the drug was assessed in 15 children (aged 2-17 years) who received high dose cyclophosphamide (on days -6 and -5) and TBI (days -3 to 0 inclusive). During days -6 to -4 when the emetic effect of cyclophosphamide would be most pronounced, 12 of the 15 patients (80%) had fewer than five emetic episodes during their worst 24-h period, 11 (73%) had fewer than three vomits whilst nine (60%) experienced no vomiting or retching. Eleven patients progressed to TBI and 10 (91%) had fewer than five emetic events in the worst 24-h period (days -3 to +2), six (55%) had no vomiting at all. Of 100 evaluable 'patient-days' 83 (83%) were without any vomiting or retching and a further 10 'patient-days' had only one or two emetic episodes. There were no significant side-effects noted and in particular no extrapyramidal reactions. Headaches and constipation, which have been seen in adult studies, were not reported by patient or parent on any of the study days and transient elevation of liver enzymes were noted in only two patients. Ondansetron has a major role in preparing patients for BMT.
authors.affiliation: Royal Hospital for Sick Children, Bristol, UK.
authors.forename: M
authors.initials: M
authors.lastname: Hewitt
authors.forename: J
authors.initials: J
authors.lastname: Cornish
authors.forename: D
authors.initials: D
authors.lastname: Pamphilon
authors.forename: A
authors.initials: A
authors.lastname: Oakhill
mesh_terms: D000293:Adolescent; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000592:standards / Q000627:therapeutic use*; D008297:Male; D017294:Ondansetron; D012702:Serotonin Antagonists / Q000592:standards / Q000627:therapeutic use*; D014839:Vomiting / Q000209:etiology / Q000517:prevention & control*; D014916:Whole-Body Irradiation / Q000009:adverse effects
chemical_list: D007093:Imidazoles; D012702:Serotonin Antagonists; D017294:Ondansetron; D003520:Cyclophosphamide